Andexxa Off The US Market

Andexanet alfa (Andexxa) will leave the US market on December 22, 2025, after AstraZeneca withdrew its biologics license application for commercial reasons. For a drug that costs as much as a car (~$25-50K per dose) and carries meaningful safety concerns… good riddance! Andexanet entered practice as the only FDA-approved reversal agent specifically targeting factor Xa […]